10.05.12
A new study verifies the beneficial role of resveratrol in the support of cardiovascular health, with results demonstrating that regular supplementation with DSM Resvida resveratrol has a positive and sustained effect on circulatory function in obese, mildly hypertensive adults. The double-blind placebo-controlled trial was conducted with 28 subjects supplemented with 75 mg of Resvida per day for six weeks. This resulted in a 23% increase in vasodilator function (measured by flow-mediated dilatation, FMD), compared with the placebo. The extent of improvement was greater in subjects with poorer initial vasodilator function. This is important as a decreased vasodilator response is an early biomarker for cardiovascular risk and associated with obesity and hypertension. The results reinforce previous findings that a single dose of Resvida can improve vasodilator function, and can result in continued improvement with regular supplementation.
For more information: www.dsm.com
For more information: www.dsm.com